Teladoc Health Inc Stock Price, News & Analysis

Teladoc Health (TDOC) has launched an at-home A1C testing program as part of its Livongo chronic care solution, enabling members to better manage diabetes. The service, provided by LetsGetChecked, allows for convenient self-testing and aims to close care gaps. Notably, 58% of members opted for the service, which boasts a significantly higher return rate than alternatives. Furthermore, 87% of users reported controlled A1C levels under 8%, compared to a 54% average in commercial health plans. This initiative enhances access to care and improves health outcomes, aligning with Teladoc's commitment to whole-person health.

Teladoc Health (NYSE: TDOC) is offering free, 24/7 telehealth visits to residents and first responders in Kentucky affected by severe storms and flooding. The service allows individuals to seek treatment for non-emergency illnesses by calling Teladoc directly. This initiative aims to maintain community health during challenging times when local healthcare services may be disrupted. Teladoc has previously provided similar services during natural disasters, supporting numerous communities across the U.S. in 2021.

Teladoc Health reported an 18% revenue increase in Q2 2022, totaling $592.4 million, driven by a 20% rise in access fees. However, the company faced a significant net loss of $3.1 billion, primarily due to a non-cash goodwill impairment charge of $3 billion. Adjusted EBITDA decreased by 30% year-over-year to $46.7 million. U.S. revenues grew 18%, while international revenues rose 13%. For Q3 2022, the company expects revenues between $600 million and $620 million, with a projected net loss per share of $0.85 to $0.60.

Teladoc Health (TDOC) has appointed Mike Waters as Chief Operating Officer, effective July 25, 2022. Waters brings over 20 years of experience in healthcare operations, joining from Providence, where he led the Ambulatory Care Network. He will work closely with CEO Jason Gorevic to enhance member services, supply chain, and provider networks, aiming for a seamless integrated care experience. Waters expressed enthusiasm for strengthening Teladoc's whole-person care solutions, aligning with the company's growth strategy and mission to improve healthcare accessibility.

Teladoc Health (NYSE: TDOC) released new clinical findings emphasizing the effectiveness of integrated care for managing multiple chronic conditions. The research indicates that their approach leads to significant improvements in A1c levels, blood pressure, and weight control compared to isolated programs. Users of their chronic care program reported enhanced satisfaction and engagement, with those involved in multiple programs showing a 2x return on investment. Teladoc is committed to value-based care with performance guarantees tied to health improvement outcomes.

Teladoc Health (NYSE: TDOC) will release its second quarter 2022 financial results on July 27, 2022, after market close. The company plans to host a conference call at 4:30 p.m. ET on the same day to review the results. Participants can join the call by dialing 1-844-200-6205 for U.S. callers or 1-929-526-1599 internationally, using access code # 303657. An audio webcast will also be available. Teladoc Health is recognized as a leader in virtual care, leveraging data-driven insights to enhance health outcomes.

Teladoc Health (NYSE: TDOC) has announced expanded capabilities for its Primary360 service, enhancing accessibility and convenience for members. Key features include health plan in-network referrals, free same-day medication delivery via Capsule, and in-home phlebotomy with Scarlet Health. The service's momentum continues as Priority Health integrates Primary360 into its offerings. Recently recognized by the CIO 100 list, Primary360 aims to improve healthcare access and support health equity.

Teladoc Health reported a first-quarter revenue increase of 25% year-over-year, totaling $565.4 million. However, the company faced a significant net loss of $6.7 billion, driven primarily by a $6.6 billion non-cash goodwill impairment charge. The adjusted EBITDA decreased 4% to $54.5 million. For 2022, Teladoc revised its guidance, anticipating revenue between $2.4 billion and $2.5 billion and a net loss per share ranging from ($43.50) to ($43.00).

Teladoc Health has appointed Dr. Vidya Raman-Tangella as Chief Medical Officer, effective April 25, 2022. Dr. Raman-Tangella will spearhead the company's clinical strategy, focusing on health equity, clinical evidence, and physician training. With over two decades of experience, she previously led healthcare solutions at Amazon Web Services. Teladoc aims to enhance patient care through data and technology, affirming its commitment to whole-person virtual care. CEO Jason Gorevic expressed enthusiasm for her leadership in pushing innovation for better health outcomes.